Cas:455941-78-3 methyl 4-(trifluoromethyl)pyridine-2-carboxylate manufacturer & supplier

Chemical Name:methyl 4-(trifluoromethyl)pyridine-2-carboxylate

CAS.NO:455941-78-3

Synonyms:Methyl 4-(trifluoromethyl)picolinate

Molecular Formula:C₈H₆F₃NO₂

Molecular Weight:205.13400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:257.35ºC at 760 mmHg

Density:1.331g/cm3

Index of Refraction:1.446

PSA:39.19000

Exact Mass:205.03500

LogP:1.88700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl 4-(trifluoromethyl)picolinate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 4-(trifluoromethyl)picolinate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 4-(trifluoromethyl)picolinate Use and application,Methyl 4-(trifluoromethyl)picolinate technical grade,usp/ep/jp grade.

Related News: The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. phenyl N-(2,2-dimethylpropyl)-N-phenoxycarbonylcarbamate manufacturers The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above, EMA said. 2-((6-methoxy-3-nitropyridin-2-yl)amino)propane-1,3-diol dihydrochloride suppliers developing a New Deal for post-graduate research students, starting later this year with a cross-sectoral consultation led by UKRI 2-[3-(diethylaminomethyl)-4-methoxyphenyl]acetohydrazide vendor & factory The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above, EMA said.,The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered.